Deramiocel(Deramiocel) - 在研适应症：杜氏肌营养不良症，贝克型肌营养不良_专利_临床

概要

基本信息

药物类型

干细胞疗法

别名

Allogeneic adult stem cell therapy for myocardial infarction(Capricor)、Allogeneic cardiosphere-derived cells(Capricor)、Allogeneic CDCs - Capricor

+ [4]

靶点-

作用方式-

作用机制

细胞替代物

治疗领域

神经系统疾病遗传病与畸形皮肤和肌肉骨骼疾病+ [1]

在研适应症

杜氏肌营养不良症贝克型肌营养不良

非在研适应症

心肌疾病扩张型心肌病新型冠状病毒感染+ [8]

原研机构

Capricor Therapeutics, Inc.

在研机构

Capricor Therapeutics, Inc.

非在研机构

Capricor, Inc.

The Medical University of South Carolina

权益机构

Nippon Shinyaku Co., Ltd.

Capricor Therapeutics, Inc.

最高研发阶段申请上市

首次获批日期-

最高研发阶段(中国)-

特殊审评孤儿药 (美国)、罕见儿科疾病 (美国)、孤儿药 (欧盟)、再生医学先进疗法 (美国)、先进治疗医药产品 (欧盟)、优先审评 (美国)

登录后查看时间轴

关联

11

项与 Deramiocel 相关的临床试验

NCT05126758

/ Active, not recruiting临床3期

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Efficacy and Safety of Human Allogeneic Cardiosphere-Derived Cells for the Treatment of Duchenne Muscular Dystrophy

HOPE-3 is a two cohort, Phase 3, multi-center, randomized, double-blind, placebo-controlled clinical trial evaluating the efficacy and safety of a cell therapy called deramiocel (CAP-1002) in study participants with Duchenne muscular dystrophy (DMD) and impaired skeletal muscle function. Non-ambulatory and ambulatory boys and young men who meet eligibility criteria will be randomly assigned to receive either deramiocel or placebo every 3 months for a total of 4 doses during the first 12 months of the study. All participants will be eligible to receive 4 doses of deramiocel for an additional 12 months as part of an open-label extended assessment period. After completion of the first open-label extension (Months 12-24), subjects who have completed Month 24 are eligible to continue onto a Long-Term Open-Label Extension period that will provide treatment with deramiocel until commercial availability, or until sponsor's decision to terminate the trial, or the participant withdraws consent.

开始日期2022-06-22

申办/合作机构

Capricor, Inc.

NCT04623671

/ Completed临床2期

A Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Intravenous Infusion of CAP-1002 in Patients With COVID-19 (INSPIRE)

This is a randomized, double-blind, placebo-controlled, Pilot, Phase 2 Exploratory study that will enroll subjects with a clinical diagnosis of COVID-19 confirmed by laboratory testing and who are in severe or critical condition as indicated by life-support measures.

开始日期2020-11-15

申办/合作机构

Capricor, Inc.

NCT04428476

/ Active, not recruiting临床2期

Open-Label Extension of the HOPE-2 Duchenne Muscular Dystrophy Trial

This Phase 2, multi-center, open-label extension trial will provide deramiocel (CAP-1002) to subjects that were enrolled in the HOPE-2 trial and completed 12 months of follow-up. The trial will explore the safety and efficacy of twenty intravenous administrations of deramiocel, each separated by three months, over a period of approximately 60 months. Following completion of the initial open-label phase (Month 60), subjects who have completed all Month 60 assessments will be eligible to continue into a long-term open label extension (LT-OLE) period and can continue to receive deramiocel once every 3 months until deramiocel is commercially available or the sponsor terminates the study, or the subject withdraws consent or study participation is terminated by the sponsor.
Subjects will undergo a targeted screening during a 30-day screening period, eligible subjects will then undergo baseline safety and efficacy assessments on Day 1 prior to their first infusion of deramiocel.
Subjects will complete trial assessments at Screening; Day 1; Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, 60, and all LT-OLE visits. Safety and efficacy assessments will be conducted prior to deramiocel administration at the Day 1, Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, and at all LT-OLE trial visits, unless otherwise indicated.
All deramiocel infusions will be conducted in an outpatient setting at the investigative site on Day 1 and Months 3, 6, 9, 12, 15, 18, 21, 24, 27, 30, 33, 36, 39, 42, 45, 48, 51, 54, 57, with continued dosing in the LT-OLE visits. Subjects will be observed in the outpatient setting for at least two hours post infusion and then discharged the same day, if medically cleared by the site Investigator.

开始日期2020-08-05

申办/合作机构

Capricor, Inc.

100 项与 Deramiocel 相关的临床结果

登录后查看更多信息

100 项与 Deramiocel 相关的转化医学

登录后查看更多信息

100 项与 Deramiocel 相关的专利（医药）

登录后查看更多信息

3

项与 Deramiocel 相关的文献（医药）

2020-07-01·Basic research in cardiology

Allogeneic cardiosphere-derived cells (CAP-1002) in critically ill COVID-19 patients: compassionate-use case series

Article

作者: Friedman, Oren ; Chen, Peter ; Marbán, Linda ; Singh, Siddharth ; Akhmerov, Akbarshakh ; Zaman, Tanzira ; Ebinger, Joseph E ; Falk, Jeremy ; Marbán, Eduardo ; Gheorghiu, Mitch ; Makkar, Raj R ; Chakravarty, Tarun

Abstract:

There are no definitive therapies for patients with severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. Therefore, new therapeutic strategies are needed to improve clinical outcomes, particularly in patients with severe disease. This case series explores the safety and effectiveness of intravenous allogeneic cardiosphere-derived cells (CDCs), formulated as CAP-1002, in critically ill patients with confirmed coronavirus disease 2019 (COVID-19). Adverse reactions to CAP-1002, clinical status on the World Health Organization (WHO) ordinal scale, and changes in pro-inflammatory biomarkers and leukocyte counts were analyzed. All patients (n = 6; age range 19–75 years, 1 female) required ventilatory support (invasive mechanical ventilation, n = 5) with PaO2/FiO2 ranging from 69 to 198. No adverse events related to CAP-1002 administration were observed. Four patients (67%) were weaned from respiratory support and discharged from the hospital. One patient remains mechanically ventilated as of April 28th, 2020; all survive. A contemporaneous control group of critically ill COVID-19 patients (n = 34) at our institution showed 18% overall mortality at a similar stage of hospitalization. Ferritin was elevated in all patients at baseline (range of all patients 605.43–2991.52 ng/ml) and decreased in 5/6 patients (range of all patients 252.89–1029.90 ng/ml). Absolute lymphocyte counts were low in 5/6 patients at baseline (range 0.26–0.82 × 103/µl) but had increased in three of these five patients at last follow-up (range 0.23–1.02 × 103/µl). In this series of six critically ill COVID-19 patients, intravenous infusion of CAP-1002 was well tolerated and associated with resolution of critical illness in 4 patients. This series demonstrates the apparent safety of CAP-1002 in COVID-19. While this initial experience is promising, efficacy will need to be further assessed in a randomized controlled trial.

2019-02-19·Neurology1区 · 医学

Cardiac and skeletal muscle effects in the randomized HOPE-Duchenne trial

1区 · 医学

Article

作者: Bharath Ambale-Venkatesh ; Raj Makkar ; Ronald G. Victor ; John Jefferies ; Bryan Goldstein ; Linda Marbán ; Eduardo Marbán ; James Fudge ; Barry Byrne ; Joao Lima ; Deborah D. Ascheim ; Janice M. Pogoda ; Mohammad R. Ostovaneh ; Rachel Ruckdeschel Smith ; Konstantinos Malliaras ; Michael Taylor ; Jeff Rudy ; Brian Fedor

OBJECTIVE:

To assess the feasibility, safety, and efficacy of intracoronary allogeneic cardiosphere-derived cells (CAP-1002) in patients with Duchenne muscular dystrophy (DMD).

METHODS:

The Halt Cardiomyopathy Progression (HOPE)-Duchenne trial is a phase I/II, randomized, controlled, open-label trial (NCT02485938). Patients with DMD >12 years old, with substantial myocardial fibrosis, were randomized (1:1) to usual care (control) or global intracoronary infusion of CAP-1002 (75 million cells). Participants were enrolled at 3 US medical centers between January and August 2016 and followed for 12 months. An independent Data and Safety Monitoring Board provided safety oversight. Cardiac function and structure were assessed by MRI, and analyzed by a blinded core laboratory. Skeletal muscle function was assessed by performance of the upper limb (PUL).

RESULTS:

Twenty-five eligible patients (mean age 17.8 years; 68% wheelchair-dependent) were randomized to CAP-1002 (n = 13) or control (n = 12). Incidence of treatment-emergent adverse events was similar between groups. Compared to baseline, MRI at 12 months revealed significant scar size reduction and improvement in inferior wall systolic thickening in CAP-1002 but not control patients. Mid-distal PUL improved at 12 months in 8 of 9 lower functioning CAP-1002 patients, and no controls (p = 0.007).

CONCLUSIONS:

Intracoronary CAP-1002 in DMD appears safe and demonstrates signals of efficacy on both cardiac and upper limb function for up to 12 months. Thus, future clinical research on CAP-1002 treatment of DMD cardiac and skeletal myopathies is warranted.

CLASSIFICATION OF EVIDENCE:

This phase I/II study provides Class II evidence that for patients with DMD, intracoronary CAP-1002 is feasible and appears safe and potentially effective.

Biomedicines

A Novel In Vitro Potency Assay Demonstrating the Anti-Fibrotic Mechanism of Action of CDCs in Deramiocel

Article

作者: Elliott, Kristi ; Li, Yujia ; Marbán, Linda ; Sun, Minghao ; Kozinova, Marya ; Nice, Justin B. ; Adachi, Stephanie

Background/Objectives: Duchenne muscular dystrophy (DMD) is characterized by progressive skeletal and cardiac muscle degeneration driven by inflammation and fibrosis, ultimately leading to cardiomyopathy and premature death. Deramiocel, an allogeneic cell therapy composed of cardiosphere-derived cells (CDCs), has demonstrated potent anti-fibrotic and immunomodulatory effects in preclinical models and clinical trials, including HOPE-2 and its open-label extension (HOPE-2 OLE), where Deramiocel treatment significantly attenuated progression of skeletal and cardiac muscle dysfunction. Methods: CDCs in Deramiocel were cultured to generate CM enriched with secreted exosomes and factors, which was subsequently applied to primary human dermal fibroblasts (HDFs). Following co-culture, ex-pression of collagen type I alpha 1 (COL1A) and collagen type III alpha 1 (COL3A) was measured by qRT-PCR. Non-conditioned media serves as a control in the assay. Reduction in COL1A and COL3A expression therefore provides a direct and clinically relevant measure of the anti-fibrotic activity of Deramiocel. Results: A novel in vitro potency assay was developed to quantify the anti-fibrotic activity of Deramiocel. Conditioned media (CM) from over one hundred Deramiocel manufacturing lots significantly suppressed expression of collagen type I alpha 1 (COL1A) and collagen type III alpha 1 (COL3A) in primary human dermal fibroblasts compared with non-conditioned media controls, establishing a robust, reproducible readout of anti-fibrotic activity. The effect was dose-dependent and abrogated by sequential depletion of exosomes and soluble proteins, implicating both as critical mediators of Deramiocel’s mechanism of action. Importantly, CDCs in Deramiocel lots classified as potent by this assay were shown to exert a clinically meaningful benefit in DMD patients in the HOPE-2 and HOPE-2 OLE studies. Conclusions: This assay represents a mechanistically informative, therapeutically relevant, reproducible, scalable, and regulatory-compliant approach for assessing Deramiocel potency, enabling consistent manufacturing, and facilitating the continued development of Deramiocel as a disease-modifying therapy for DMD.

493

项与 Deramiocel 相关的新闻（医药）

2026-08-28

·今日头条

细胞科技一周资讯：全球首款外泌体疗法11月迎FDA终审

▍江苏正式出台《江苏省促进生物医药产业高质量发展三年行动计划》为加快培育具有国际竞争力的生物医药产业集群，打造生物医药新兴支柱产业，江苏省工业和信息化厅8月26日正式对外发布《江苏省促进生物医药产业高质量发展三年行动计划》，目标到2028年，全省生物医药产业规模、创新药械数量保持全国领先，打造一批具有核心竞争力的生物医药产业集聚区。 ▍ 上肢衰退减缓54%！全球首款外泌体疗法11月迎FDA终审当地时间8月24日，Capricor Therapeutics宣布，FDA已将其在研细胞疗法Deramiocel（CAP-1002）治疗杜氏肌营养不良症（DMD）的BLA的PDUFA目标行动日期，从2026年8月22日延期至11月22日。该BLA于2024年12月以心肌病方向提交，依据II期HOPE-2研究及其开放标签延伸研究的心脏数据；2025年7月曾收到FDA完全回应函，本次为第二次审查。 ▍ 2026 年上半年 CAR-T 销售额出炉：超 30 亿美元 2025 年，全球 7 款获 FDA 批准上市 CAR‑T 药物全年总销售额为 59.67 亿美元，同比增长 31.66%。其中，强生/传奇生物 Carvykti、吉利德 Yescarta 以及 BMS Breyanzi 三款头部药物合计贡献 47.4 亿美元，占总规模的 79%。进入 2026 年上半年，5 款具备完整统计口径的 CAR-T 药物合计实现销售额超 30 亿美元，赛道马太效应持续强化。 ▍ NMPA 发布《国家重点研发计划重点专项管理实施细则》近日，国家药监局发布了《国家药品监督管理局主责国家重点研发计划重点专项管理实施细则》的征求意见稿，文件强调了国家药监局作为「主责单位」的角色，即：国家药监局从以往的参与者转变为医药领域重点专项的牵头组织者和责任者。

2026-08-27

·植物囊泡KZD

外泌体细胞疗法突破 III 期！冲刺晚期 DMD 上肢功能新赛道，有望开创全新治疗里程碑

罕见病领域，一直是新药研发最难啃的一块阵地。而杜氏肌营养不良症（DMD），更是无数患者家庭心中沉重的枷锁。作为一种由抗肌萎缩蛋白缺失引发、几乎专发于男孩的 X 连锁致命遗传病，患者的肌肉会随着病程推进发生不可逆的进行性退化。从慢慢丧失行走能力，到上肢、呼吸肌、心肌接连受损，最后因心力衰竭、呼吸衰竭走向生命终点。时至今日，临床上依旧缺少可以逆转晚期病程、长期保住患者自主生活能力的根治方案。无数已经无法行走的晚期 DMD 患者，只能眼睁睁看着自己上肢功能一点点流失，慢慢失去独立吃饭、操作轮椅、与人沟通的能力。巨大的临床空白，迫切需要全新的治疗手段来破局。就在这样的行业背景之下，来自 Capricor Therapeutics 的候选细胞疗法 Deramiocel（CAP‑1002），凭借重磅 III 期临床数据，向着晚期无行走能力 DMD 患者的上肢功能治疗适应症发起最后的商业化冲刺。最新刊发于《柳叶刀》的 HOPE‑3 随机、双盲、安慰剂对照 III 期试验结果，为这款疗法筑牢了上市根基。这项研究共入组 106 名 DMD 患者，成功达成预设主要终点。数据表明，相较于安慰剂，Deramiocel 可将患者上肢功能的衰退速度减缓 54%（PUL 2.0 评估，p=0.03）。这也是全球首个在已经丧失行走能力的 DMD 人群当中，证实药物能够带来实质性肢体功能获益的 III 期研究。加州大学戴维斯分校 Craig McDonald 教授作为项目牵头研究者，高度认可该项成果的临床价值。这项试验结果也直接推动企业调整了申报策略。回顾最初的申报规划，Deramiocel 最早瞄准 DMD 心肌病适应症提交上市申请，然而 7 月底 FDA 专家咨询委员会投票显示，现有临床证据不足以支撑心脏疗效，心脏方向并未获得专家组青睐。反观上肢功能终点的数据表现亮眼，企业随即调整重心，将本次上市申报的主攻方向切换至改善晚期患者上肢骨骼肌功能，并补充 24 个月开放标签延展数据集与多维度稳健性分析材料，提交至 FDA，而FDA将其归类为“重大修订”，延长三个月审查时间。上肢功能对于晚期 DMD 患者，是维持生活自主权的最后一道关键防线。一旦上肢能力快速退化，患者将会逐步失去自主进食、操控轮椅、使用通讯设备的能力，彻底丧失独立生活的基础。因此，能够延缓上肢衰退的疗法，刚好填补了目前临床上一块巨大的未被满足的治疗缺口。从作用机理来看，Deramiocel 是一款同种异体心脏球源细胞产品，其治疗效应主要依靠细胞分泌的外泌体实现。药物通过重编程巨噬细胞，引导促炎型巨噬细胞向修复表型转化，以此抑制炎症反应、减缓肌肉组织纤维化进程。在一众外泌体相关管线当中，它也是全球商业化进度最领先的候选产品之一。得益于突出的潜力，该疗法早已收获国内外多项重磅认定：FDA 孤儿药资格、再生医学先进疗法（RMAT）、罕见儿科疾病资格；欧盟 EMA 孤儿药以及 ATMP 先进疗法药品资质。如若顺利获批，企业还将收获一张 FDA 优先审评券。如果本次上肢适应症顺利通过 FDA 审批，Deramiocel 将一举成为全球首款用于 DMD 的获批细胞治疗产品，同时开启外泌体机制细胞疗法商业化的新时代，为广大晚期杜氏肌营养不良患者带来全新的生存希望。相关文章：专利加持｜凯之迪攻克植物囊泡纯化难题，解锁规模化制备新路径从实验室到工厂，一条植物囊泡生产线是怎么建成的？凯之迪 X10 外泌体提纯系统全新升级！一次性 + 可重复灭菌，零污染天花板来了外泌体研发与市场全景报告 —— 聚焦TFF+SEC+单次性工艺落地及艾迪迈装备应用团标解读中草药囊泡标准化时代| 艾迪迈科技旗下凯之迪携规模化制备方案推动产业升级艾迪迈旗下凯之迪科技成立于2022年，是国内首创的植物囊泡提取、纯化、检测及工业量产整体解决方案供应商，可提供全套装备、材料及技术方案，在重庆建设有国内首家规模化1500㎡十万级GMP级别CDMO生产示范基地、功效评价实验室及产品研发中心，2025年获批共建重庆市新型中药生物活性产物技术创新中心。全国服务热线：400 168 5509 公司网址：http://www.aidimai.com/

2026-08-27

·微信

新锐达成1亿美元潜在“first-in-class”多肽疗法交易；治疗DMD，潜在“first-in-class”细胞疗法公布最新监管进展

新锐达成1亿美元潜在“first-in-class”多肽疗法交易 Zealand Pharma近日宣布，与Royalty Pharma达成一项特许权使用费购买与出售协议，将其与在研药物rusfertide（PTG-300）相关的部分经济权益出售给后者，交易总额为1亿美元。根据协议，其中5000万美元将在交易完成时支付，另外5000万美元将在交易完成一周年时支付。Rusfertide拟用于治疗罕见慢性血液疾病真性红细胞增多症（PV），美国FDA已将其新药申请（NDA）的PDUFA目标日期设定在2026年第三季度。根据之前合作协议，武田（Takeda）将负责该药物的全球商业化。 Rusfertide是一款潜在“first-in-class”的在研皮下注射疗法，通过模拟天然激素铁调素（hepcidin）的作用，调节铁稳态和红细胞生成。该药旨在针对真性红细胞增多症中铁调节异常这一疾病机制，减少过量红细胞生成，并帮助患者实现持续的红细胞压积控制。目前，rusfertide采用每周一次皮下自行注射的给药方式，在迄今开展的临床试验中总体耐受性良好。2026年3月，美国FDA受理rusfertide的新药申请并授予优先审评资格。该申请主要基于3期全球随机研究VERIFY的积极结果，以及2期REVIVE及长期扩展研究的数据。治疗DMD，潜在“first-in-class”细胞疗法公布最新监管进展 Capricor Therapeutics近日在公布2026年第二季度财报时表示，在美国FDA咨询委员会对其杜氏肌营养不良（DMD）细胞疗法deramiocel作出不利投票结果后，公司计划向FDA提交更多临床数据和分析，并计划进一步调整拟申请的适应症范围，以HOPE-3试验的主要终点——上肢功能——作为核心支持证据。。该公司计划提交HOPE-3研究24个月开放标签延长期数据，并对现有数据包开展进一步分析。值得一提的是，FDA咨询委员会在当时并未就3期HOPE-3试验的主要终点或整体获益-风险进行表决；而在关于上肢功能的单独讨论环节中，委员会对HOPE-3相关临床证据的反馈总体呈支持方向。根据行业媒体Endpoints News报道，FDA已表示愿意审查这一补充材料，并将在收到后相应延长PDUFA目标日期。目前deramiocel的PDUFA目标日期为2026年8月22日，但公司尚未公布补充材料的具体提交时间。 Deramiocel（又名CAP-1002）是一种潜在“first-in-class”同种异体细胞疗法，由心脏来源细胞（CDCs）组成。该疗法最初的开发目标之一是治疗DMD患者的心肌病，但Capricor目前计划调整监管申请策略，将拟申请的适应症进一步聚焦于HOPE-3试验的主要终点。HOPE-3完整3期数据已于2026年7月发表于《柳叶刀》。研究显示，deramiocel可显著减缓PUL 2.0评估的上肢功能下降（p=0.029），其他功能及心脏指标亦显示出支持性结果。参考资料： [1] Zealand Pharma enters into a USD 100 million royalty purchase and sale agreement with Royalty Pharma for the economics related to rusfertide. Retrieved August 14, 2026 from https://www.globenewswire.com/news-release/2026/08/12/3344048/0/en/zealand-pharma-enters-into-a-usd-100-million-royalty-purchase-and-sale-agreement-with-royalty-pharma-for-the-economics-related-to-rusfertide.html?_gl=1*k0phv*_up*MQ..*_ga*OTMxODkyMzIuMTc4NjU3NDA2NA..*_ga_B6167QB2TF*czE3ODY1NzQwNjMkbzEkZzAkdDE3ODY1NzQwNjMkajYwJGwwJGgyMDQzOTYyMzYw*_ga_ERWPGTJ5X8*czE3ODY1NzQwNjMkbzEkZzAkdDE3ODY1NzQwNjMkajYwJGwwJGgw [2] Capricor Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update. Retrieved August 14, 2026 from https://www.capricor.com/investors/news-events/press-releases/detail/353/capricor-therapeutics-reports-second-quarter-2026-financial [3] Capricor, seeking lifeline for Duchenne therapy, says it will ask FDA to review additional data. Retrieved August 14, 2026 from https://endpoints.news/capricor-seeking-lifeline-for-duchenne-therapy-says-it-will-ask-fda-to-review-additional-data/ 免责声明：本文仅作信息交流之目的，文中观点不代表药明康德立场，亦不代表药明康德支持或反对文中观点。本文也不是治疗方案推荐。如需获得治疗方案指导，请前往正规医院就诊。版权说明：欢迎个人转发至朋友圈，谢绝媒体或机构未经授权以任何形式转载至其他平台。转载授权请在「药明康德」微信公众号回复“转载”，获取转载须知。分享，点赞，在看，传递医学新知

100 项与 Deramiocel 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
杜氏肌营养不良症	申请上市	美国	Capricor Therapeutics, Inc.	2026-03-10
新型冠状病毒感染	临床2期	美国	Capricor, Inc.	2020-11-15
射血分数保留型心力衰竭	临床2期	美国	The Medical University of South Carolina	2017-07-12
舒张期心力衰竭	临床2期	美国	The Medical University of South Carolina	2017-07-12
心肌疾病	临床2期	美国	Capricor, Inc.	2016-01-07
脊髓痨	临床2期	美国	Capricor, Inc.	2016-01-07
非ST段抬高型心肌梗死	临床2期	美国	Capricor, Inc.	2012-11-13
ST段抬高心肌梗死	临床2期	美国	Capricor, Inc.	2012-11-13
左心室功能不全	临床2期	美国	Capricor, Inc.	2012-11-13
扩张型心肌病	临床1期	美国	Capricor, Inc.	2014-11-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05126758 (HOPE-3, GlobeNewswire) 人工标引	临床3期	杜氏肌营养不良症	106	Deramiocel	積獵壓網選憲鬱網觸築(衊願簾鑰願願糧鏇廠鹽) = 壓構簾觸鏇觸網廠鏇築夢鑰鑰獵積鏇鬱齋窪範 (築遞鏇遞憲簾廠夢鬱積 ) 达到更多	积极	2025-12-03
				Placebo	-
NCT04428476 (HOPE-2-OLE, GlobeNewswire) 人工标引	临床2期	杜氏肌营养不良症	-	Deramiocel	觸願壓艱窪蓋衊壓膚鏇(淵製鹽鏇餘築鹹簾範艱) = 襯襯遞蓋淵鑰糧獵繭遞窪蓋衊製壓艱願鏇繭憲 (鏇築淵鑰夢糧觸製廠鹹 )	积极	2025-03-17
				External Comparator Group	觸願壓艱窪蓋衊壓膚鏇(淵製鹽鏇餘築鹹簾範艱) = 簾選範鏇選齋齋憲襯糧窪蓋衊製壓艱願鏇繭憲 (鏇築淵鑰夢糧觸製廠鹹 )
NCT03406780 (HOPE-2, CTgov)	临床2期	杜氏肌营养不良症	20	CAP-1002 (CAP-1002)	餘鏇鏇餘艱齋網築憲窪(壓願餘糧製範壓窪鑰壓) = 製齋糧廠廠淵選鬱壓製遞窪選醖願餘鹽廠蓋願 (顧鹹蓋鹹繭艱鹽簾獵簾, 10.82) 更多	-	2025-02-24
				Placebo (Placebo)	餘鏇鏇餘艱齋網築憲窪(壓願餘糧製範壓窪鑰壓) = 窪齋鏇憲鑰廠積餘簾衊遞窪選醖願餘鹽廠蓋願 (顧鹹蓋鹹繭艱鹽簾獵簾, 9.23) 更多
NCT04428476 (HOPE-2 OLE \| HOPE-2-OLE, CTgov)	临床2期	杜氏肌营养不良症	13	CAP-1002	簾願蓋網積築壓鏇鏇艱 = 蓋衊遞築築願觸餘構餘鏇鏇顧遞鏇憲廠膚艱壓 (膚遞選艱蓋膚繭壓選網, 顧選構築築憲網憲艱構 ~ 壓獵艱壓廠襯築鏇鏇鹽) 更多	-	2025-02-24
NCT04623671 (INSPIRE, CTgov)	临床2期	新型冠状病毒感染	55	CAP-1002 (CAP-1002)	糧醖醖選鹽淵願艱構願 = 顧積獵餘糧範廠糧憲鏇願齋憲鬱齋餘醖壓網鏇 (蓋衊遞廠範觸齋願糧築, 觸製積衊餘鹽鬱網製鬱 ~ 衊網築鏇齋繭夢範夢願) 更多	-	2025-02-20
				Placebo (Placebo)	糧醖醖選鹽淵願艱構願 = 淵鹹構糧範襯繭製衊鏇願齋憲鬱齋餘醖壓網鏇 (蓋衊遞廠範觸齋願糧築, 齋選廠觸壓簾網積衊膚 ~ 簾糧顧窪鬱壓繭廠襯壓) 更多
NCT04428476 (HOPE-2 OLE, GlobeNewswire) 人工标引	临床2期	杜氏肌营养不良症	-	Deramiocel	窪鑰艱製繭選鏇鏇製繭(鑰艱獵鑰衊淵鏇廠遞壓) = 壓鑰觸膚廠願繭築鹹範憲願積製簾糧壓醖壓遞 (遞遞網網鑰窪醖選遞廠 )	积极	2024-10-11
NCT02941705 (RegressHFpEF, CTgov)	临床2期	射血分数保留型心力衰竭 \| 舒张期心力衰竭	27	Allogeneic Derived Cells (RECIEVED CELLS)	糧顧鬱願積餘範積獵獵 = 願糧鹹壓鏇膚遞鏇醖選遞積夢壓築襯糧鹽積壓 (選鹽積艱廠齋願鏇憲齋, 餘遞簾鏇鏇鏇鹽遞鑰蓋 ~ 齋壓遞廠壓觸獵繭遞廠) 更多	-	2024-07-25
				Placebo/Control Arm (CONTROL ARM)	糧顧鬱願積餘範積獵獵 = 窪遞衊願鹹淵衊顧遞積遞積夢壓築襯糧鹽積壓 (選鹽積艱廠齋願鏇憲齋, 襯鏇製醖構餘製鏇選顧 ~ 觸廠衊鹽艱夢衊蓋積鹹) 更多
NCT04428476 (HOPE-2-OLE, Biospace) 人工标引	临床2期	杜氏肌营养不良症	20	CAP-1002	鏇壓鬱繭蓋憲鹽獵鬱蓋(淵憲範齋選選遞鑰願鹽) = 鏇選餘築膚夢遞夢醖醖窪積構鹽鏇構餘廠鬱衊 (衊構構餘鑰願願簾製憲 )	积极	2024-06-04
				External Comparator	鏇壓鬱繭蓋憲鹽獵鬱蓋(淵憲範齋選選遞鑰願鹽) = 鬱醖鑰膚壓築範壓遞鹽窪積構鹽鏇構餘廠鬱衊 (衊構構餘鑰願願簾製憲 )
NCT06304064 (HOPE-OLE \| CAP-1002-DMD-03, CTgov)	临床2期	杜氏肌营养不良症	8	CAP-1002	醖齋餘壓鹽醖艱壓窪壓 = 鹹窪構淵餘簾淵範觸衊齋獵構壓觸積蓋憲鹹衊 (顧鑰壓積鹽築築憲選遞, 鹽遞憲構範鑰鹹衊構夢 ~ 鏇簾鑰構艱顧餘襯鏇糧) 更多	-	2024-04-24
NCT01458405 (ALLSTAR, CTgov)	临床1/2期	左心室功能不全 \| 心肌梗塞 \| 非ST段抬高型心肌梗死 ... 更多	135	placebo (Randomized Treatment Cohort: Placebo)	築積鹽願餘鏇繭願窪壓 = 淵鑰鑰遞糧憲窪膚構鏇艱齋觸衊製襯範選選窪 (構窪淵醖糧淵願膚鹹鬱, 壓遞觸繭簾鹽鑰鹽壓顧 ~ 鏇淵選壓選窪簾憲鏇蓋) 更多	-	2024-04-09
				CAP-1002 (Randomized Treatment Cohort: CAP-1002 Allogeneic Cardiosphere-Derived Cells)	築積鹽願餘鏇繭願窪壓 = 鏇壓願鹽艱顧願繭簾構艱齋觸衊製襯範選選窪 (構窪淵醖糧淵願膚鹹鬱, 壓獵網蓋膚鏇蓋製壓築 ~ 獵齋鏇願糧壓膚繭鏇獵) 更多